New drug combo aims to shrink tumors for pancreatic cancer surgery
NCT ID NCT07415525
Summary
This study is testing whether a new drug called IBI343, when given with standard chemotherapy before surgery, can help control borderline resectable pancreatic cancer. It aims to shrink tumors so they can be surgically removed, followed by more chemotherapy after surgery. The trial will enroll 40 adults with a specific tumor marker (CLDN18.2-positive) who have not had prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.